Granulomatous dermatitis secondary to vemurafenib in a child with Langerhans cell histiocytosis

Lily Chen, Andy C. Hsi, Alok Kothari, Louis P. Dehner, Robert J. Hayashi, Carrie C. Coughlin

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

We present a 3-year-old boy with Langerhans cell histiocytosis who developed granulomatous dermatitis while taking vemurafenib. Vemurafenib currently has Food and Drug Administration approval for the treatment of BRAF V600E+ metastatic melanoma in adults, but recent discoveries of BRAF V600E in more than half of tested Langerhans cell histiocytosis lesions have prompted clinical trials of vemurafenib therapy for children with refractory, multisystem Langerhans cell histiocytosis. This report contributes to the knowledge of its potential side effects when used in children.

Original languageEnglish
Pages (from-to)e402-e403
JournalPediatric Dermatology
Volume35
Issue number6
DOIs
StatePublished - Nov 1 2018

Keywords

  • BRAF inhibitor
  • granulomatous dermatitis
  • pediatric
  • targeted therapy

Fingerprint

Dive into the research topics of 'Granulomatous dermatitis secondary to vemurafenib in a child with Langerhans cell histiocytosis'. Together they form a unique fingerprint.

Cite this